Quantcast

Latest Factor VII Stories

2011-04-25 08:30:00

WAYNE, N.J., April 25, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved a new storage option for Kogenate® FS, antihemophilic factor (recombinant), now allowing the product to be stored at room temperature (up to 77 degrees F) for up to one year. Compared with the previous three-month room temperature option, this new storage option for Kogenate FS offers added convenience for patients...

2011-04-14 11:00:00

WAYNE, N.J., April 14, 2011 /PRNewswire/ -- To help raise money and awareness for bleeding disorders, Bayer is launching the 2011 Bayer Virtual Walk for Hemophilia, the first interactive program of its kind in support of people with hemophilia. The Virtual Walk is Bayer's latest digital offering for the hemophilia community. The company is asking people to step up for an important cause by virtually walking online for the National Hemophilia Foundation (NHF) and its local participating...

2011-02-03 01:30:00

GENEVA, Feb. 3, 2011 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today presented pharmacokinetic (PK) data on its lead product, IB1001, a recombinant factor IX (FIX) for the treatment and prevention of bleeding in individuals with hemophilia B. Results of the Phase 1 portion of an ongoing IB1001 clinical study demonstrated non-inferiority of IB1001 in achieving overall levels of replacement factor compared to BeneFIX®, the only approved recombinant...

2011-02-02 06:30:00

NES-ZIONA, Israel, Feb. 2, 2011 /PRNewswire/ -- PROLOR Biotech, Inc., (NYSE Amex: PBTH), today reported positive results from a comparative study of its biobetter longer-acting version of the hemophilia drug Factor IX (Factor IX-CTP) in Factor IX-depleted hemophilic mice. The study was designed to measure the potential increase in clotting activity and duration of therapeutic effect of PROLOR's long-acting CTP-modified Factor IX when compared with commercially available recombinant...

2011-01-11 09:47:14

(Ivanhoe Newswire) -- A new editorial article, published in the Canadian Medical Association Journal, suggests physicians should be more careful when prescribing drugs "off-label." The use of the drug recombinant activated factor 7 (rFVIIa), despite its potential for adverse events, shows the serious shortcomings of Canada's current drug surveillance system, according to the commentary. Off-label use of this therapy, which is a blood product, was driven by key physician opinion leaders who...

2011-01-10 14:49:07

The use of recombinant activated factor 7 (rFVIIa) despite its potential for adverse events displays the serious shortcomings of Canada's current drug surveillance system, according to a commentary published in CMAJ (Canadian Medical Association Journal) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj101842.pdf. Off-label use of this therapy "” a blood product "” was driven by key physician opinion leaders who thought recombinant factor VIIa could be used to treat or...

2010-12-16 07:30:00

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2010 /PRNewswire/ -- Catalyst Biosciences, Inc., the leading company in the discovery and development of engineered proteases, today announced the receipt of a $4.0 million milestone payment from Pfizer Inc. under the terms of the collaboration agreement for the development of improved recombinant human Factor VIIa variants for the treatment of hemophilia and other bleeding disorders. "We are very encouraged by the progress made to date in our...

2010-11-19 00:30:00

LAGUNA NIGUEL, Calif., Nov. 19, 2010 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced the Company has initiated treatment of patients in a pivotal clinical study of OBI-1, an intravenous recombinant porcine factor VIII (FVIII) product, for the treatment of acquired hemophilia A, a rare, though potentially life-threatening bleeding disorder. Based on a partnership agreement signed with Ipsen SA (Euronext: IPN; ADR: IPSEY) in January 2010, Inspiration has...

2010-11-15 20:33:09

The use of recombinant activated factor 7 (rFVIIa) "“ a drug used to treat bleeding in hemophiliacs "“ in patients without hemophilia is not recommended because of the potential for adverse events, found a study published in CMAJ (Canadian Medical Association Journal) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj100408.pdf. Recombinant activated factor 7 is a hemostatic agent licensed for the treatment of bleeding in hemophilia patients. It is also used "off-label" for...

2010-11-05 06:30:00

LAGUNA NIGUEL, Calif., Nov. 5, 2010 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced the Company was awarded two grants, totaling $488,958, under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP). The grants are being provided under section 48D of the Internal Revenue Code, enacted as part of the Patient Protection and Affordable Care Act of 2010. The grants will be used to advance the clinical development of Inspiration's lead product...


Word of the Day
cock-a-hoop
  • Exultant; jubilant; triumphant; on the high horse.
  • Tipsy; slightly intoxicated.
This word may come from the phrase 'to set cock on hoop,' or 'to drink festively.' Its origin otherwise is unclear. A theory, according to the Word Detective, is that it's a 'transliteration of the French phrase 'coq a huppe,' meaning a rooster displaying its crest ('huppe') in a pose of proud defiance.' Therefore, 'cock-a-hoop' would 'liken a drunken man to a boastful and aggressive rooster.'
Related